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Accepted 6 September 2016Background. The obesogenic potential of high-fat diets (HFD) in rodents is attenuated
when the protein:carbohydrate ratio is increased. However, it is not known if intake of an
HFD irrespective of the protein:carbohydrate ratio and in the absence of weight gain, affects
glucose homeostasis and the gut microbiota.
Methods. We fed C57BL6/J mice 3 different HFDs with decreasing protein:carbohydrate
ratios for 8 weeks and compared the results to a LFD reference group. We analyzed the gut
microbiota composition by 16S rDNA amplicon sequencing and the intestinal gene
expression by real-time PCR. Whole body glucose homeostasis was evaluated by insulin
and glucose tolerance tests as well as by a hyperinsulinemic euglycemic clamp experiment.
Results. Compared with LFD-fed reference mice, HFD-fed mice, irrespective of
protein:carbohydrate ratio, exhibited impaired glucose tolerance, whereas no differences
were observed during insulin tolerance tests. The hyperinsulinemic euglycemic clamp
revealed tissue-specific effects on glucose homeostasis in all HFD-fed groups. HFD-fed mice
exhibited decreased insulin-stimulated glucose uptake in white but not in brown adipose
tissue, and sustained endogenous glucose production under insulin-stimulated conditions.
We observed no impairment of insulin-stimulated glucose uptake in skeletal muscles of
different fiber type composition. HFD-feeding altered the gut microbiota compositionKeywords:
Intestinal epithelial cells
Weight stability
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Feeding behavior
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gluconeogenesis in intestinal epithelial cells of the jejunum.
Conclusions. Intake of a HFD profoundly affected glucose homeostasis, gut inflammatory
responses, and gut microbiota composition in the absence of fat mass accretion.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Table 1 – Diet composition.
MASS (g/kg) LFD HFHP HFIP HFNP
Casein 200 500 350 200
L-cystine 3 3 3 3
Corn starch 489.5 9.5 9.5 9.5
Cellulose 50 50 50 50
Sucrose 130 130 280 430
Corn oil 70 250 250 250
Choline bitartrate 2.5 2.5 2.5 2.5
Vitamine mix AIN-93-VX 10 10 10 10
Mineral mix AIN 93 45 45 45 45
t-Butylhydroquinone 0.014 0.014 0.014 0.014
Total 1000 1000 1000 1000
Energy content (kJ/kg) 16,972 20,572 20,572 20,572
Diet composition. Comparison between the LF reference diet and
the 3 eucaloric HFDs.1. Introduction
High fat diet-induced obesity is frequently used to studyobesity
and related metabolic disorders in rodents. Since such a model
cannot be used to distinguish whether the observed metabolic
dysfunctions result from the obese state or from the high fat
feeding, the health consequences of a high fat intake, in the
absence of weight gain, remain largely unknown. Using rodent
models to elucidate the influence of dietary fat, while eliminat-
ing weight gain as confounder, is a challenging approach as
high fat diet (HFD)-feeding tends to induce obesity to various
degree depending on the protein:carbohydrate ratio [1]. Never-
theless, glucose intolerance induced by conventional HFD-
feeding has been shown to precedeweight gain in both humans
[2] and mice [3], suggesting that a HFD per se affects glucose
homeostasis. In support, we have previously demonstrated
how exchanging sucrose with casein in an isoenergetic HFD
protects against weight gain, but not glucose intolerance [1,4].
The mechanism behind the observed decrease in glucose
tolerance remains elusive. Reduced adipose plasticity affecting
both local and global insulin signaling [5], and further aggra-
vated by accompanying adipocyte inflammation, may be
involved [6]. Yet, whether adipocyte inflammation is a conse-
quence [7] or a promoter [8,9] of insulin resistance remains to be
established. Apart from changes in adiposity and adipocyte
function, HFDs promote intestinal alterations such as increased
intestinal permeability [10] and an elevated inflammatory
milieu [11]. Both factors are believed to contribute to the
progression of insulin resistance [12]. Interestingly, gut anti-
inflammatory agents have been shown to protect against HFD-
induced glucose intolerance and insulin resistance despite
significant weight gain [13], indicating intestinal inflammation
as key in the development of insulin resistance.
We hypothesized that dietary fat, independent of weight
gain, would change the intestinal microenvironment trans-
lating to impaired metabolic homeostasis. To disentangle the
influence of HFD-feeding on intestinal inflammation and
whole-body glucose disposal, we fed mice 3 experimental
isoenergetic HFDs with fixed fat content and a stepwise
increase in the protein:carbohydrate ratio and compared the
results to a low fat diet (LFD) reference group. We took
advantage of an in-house observation where mice appeared
less prone to diet-induced obesity (DIO) in 1 out of our 5
animal facilities, which reflects a recent report deciphering
how mouse origin and housing conditions influence weight
development [14]. Using the hyperinsulinemic euglycemic
clamp technique, this experimental setting enabled acquisi-
tion of information on the extent to which macronutrient
composition affects whole-body metabolismwithout possible
confounding effects of weight gain and adipose tissue
inflammation.2. Materials and Methods
2.1. Mice and Ethical Statements
Wildtype C57BL/6J male mice (Taconic Biosciences, Denmark)
were 6–8 weeks of age at delivery and single-housed for
acclimatization one week prior to the start of the experiment.
All experiments were conducted in accordance with national
Danish guidelines (amendment #1306 of November 23, 2007) as
approved by the Danish Animal Experiments Inspectorate
(#2014-15-2934-01,027). Micewere kept under specific pathogen
free conditions at 22 °C in 12 h light/dark cycle (7 AM–7 PM).
2.2. Experimental Outline and Diets
Twenty-four mice entered the experiment on a weekly basis
for 3 consecutive weeks, and mice were kept on their
respective diets for 8 weeks. Experimental diets were obtain-
ed from Ssniff (Germany) and kept at −20 °C until use. Mice
were ad libitum fed 1 of 4 different diets (Table 1): 1) LFD – low
fat control diet where sucrose and protein content mirrored
the lowest amount in any of the HFDs; 2) HFHP – HFD with
normal sucrose but high protein content; 3) HFIP – HFD with
intermediate protein and sucrose content; 4) HFNP – HFDwith
normal protein but high sucrose content. We used corn oil,
high in polyunsaturated and low in saturated fat, as fat source
to minimize the likelihood of adipose tissue inflammation.
Because both protein and carbohydrate sources affect host
metabolism, we standardized our diets using casein as
protein source and high-glycemic index sucrose as main
carbohydrate source. After 5 and 6 weeks on the experimental
diets mice were subjected to an insulin tolerance test (ITT)
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MR-scanned prior to the ITT using EchoMRI 4in1 (USA). After
7 weeks, a subset of mice in each group underwent a surgical
procedure (see Section 2.4. for further details). The remaining
mice were used as donor mice to ensure adequate red blood
cells (RBCs) during the clamp procedure.
2.3. Insulin/Glucose Tolerance Tests and HOMA-IR
Prior to the ITT and the GTT mice were fasted for 2 h and 5 h,
respectively, in clean cages only containing a transparent
shelter, bedding and water. Insulin was diluted in succinylated
gelatin (Gelofusine® B. BraunMelsungen AG, Germany). Insulin
(0.75 U insulin/kg lean mass) and glucose (2 g glucose/kg lean
mass) were injected intraperitoneally. Blood glucose was
measured in tail vein blood before and 15, 30, 45, 60, 90, and
120 min after the glucose bolus or the insulin bolus, using
Contour Next Test Strips (Bayer Contour, USA). HOMA-IR was
measured 6 weeks after diet initiation in 5 h fasted mice and
calculated as: (fasting plasma glucose (mmol/L) × fasting serum
insulin (mU/L))/22.5.
2.4. Hyperinsulinemic Euglycemic Clamp Experiments
The hyperinsulinemic euglycemic clamp was performed in
conscious, unrestrained mice. For the surgical catheterization
of the jugular vein and the carotid artery, the mice were
anesthetized with isoflurane (2.5% for induction, 1.5% for
maintenance). Carprofen (10 mg/kg; Rimadyl, Pfizer, USA) was
administered preoperatively for analgesia. After surgery, the
catheterswere lockedwithheparinized saline (200 U/ml) and the
animals recovered for 6 days. Body weight was recorded daily
during the recovery period, and mice with a weight loss of more
than 10%or a hematocrit level below 35%by day 6were excluded
from the study. On the day of the clamp experiment, mice were
fasted for 5 h starting at 7 AM (t = −300 min) by placing them in a
clean cage with bedding and nestingmaterial, and free access to
water. A divider was placed in the cage restricting the accessible
area to ~20 × 20 cm. At t = −180 min the catheters were flushed
with heparinized saline (10 U/ml) and themouse was connected
to the infusion lines. A tracer equilibration period was started at
t = −90 min by infusion of a 1.2 μCi priming dose of [3-3H]glucose
(Perkin Elmer, USA) followed by a constant 0.04 μCi/min infusion
of [3-3H]glucose for 90 min. Blood samples for the assessment of
hematocrit levels as well as basal glucose levels and turnover
rates were collected at t = −15 min (50 μl) and −5 min (100 μl),
respectively. The clamp was initiated at t = 0 min with contin-
uous infusions of human insulin (4 mU kg−1 min−1; Actrapid,
Novo Nordisk, Denmark) and washed red blood cells obtained
from a donor mouse to compensate for the blood loss due to
repeated sampling (5 μl/min of 50% RBC in 10 U/ml heparinized
saline). Bloodglucosewasmeasuredevery 10 min (BayerContour,
USA) and euglycemia (~5 mmol/L) was maintained by adjusting
a variable infusion of 50% glucose containing 0.06 μCi/μl of
[3-3H]glucose tracer. Between t = 80 and t = 120 min blood
samples (50–100 μl) were collected in 10 min intervals and
processed for determination of [3-3H]glucose specific activity.
At t = 120 min, a 12 μCi bolus of 2-[1-14C]-deoxy-D-glucose (Perkin
Elmer, USA) was injected and blood samples were collected at t =
122, 125, 135, 145, and 155 min, respectively. These samples wereprocessed for determination of 2-[1-14C]-deoxy-D-glucose specific
activity. After the final blood sample,micewere euthanizedwith a
lethal dose of pentobarbital and tissues were collected and snap-
frozen in liquid nitrogen. The tissues were processed for determi-
nation of 2-[1-14C]-deoxy-D-glucose specific activity in order to
calculate tissue-specific glucose uptake.
2.5. Clamp Sample Processing and Calculations
PlasmasamplesweredeproteinizedwithBa(OH)2 andZnSO4, and
aliquots of each supernatant were transferred to 2 scintillation
vials. To determine plasma [3-3H]glucose, one of the aliquotswas
dried and resuspended in MilliQ water to remove 3H2O and the
other was counted directly by liquid scintillation counting (Hidex
300 SL). Supernatants for 2-[1-14C]-deoxy-D-glucose determina-
tions were counted directly. Total plasma glucose concentration
was determined by adding a reaction mix (200 mmol/L Tris–HCl,
500 mmol/L MgCl2, 5.2 mmol/L ATP, 2.8 mmol/L NADP, and
148 μg of a hexokinase and GPDH mixture (Roche, Germany)
pH 7.4) to each sample. Parameters related to glucose turnover
rates (Ra, Rd., endoRa, glycolysis) were calculated as previously
described [15]. Tissues were homogenized in ice-cold lysis buffer
(pH 7.4, 10% glycerol, 1% IGEPAL, 50 mmol/L Hepes, 150 mmol/L
NaCl, 10 mmol/L NaF, 1 mmol/L EDTA, 1 mmol/L EGTA,
20 mmol/L sodium pyrophosphate, 2 mmol/L sodium
orthovanadate, 1 mmol/L sodium-pyrophosphate, 5 mmol/L
nicotinamide, 4 μmol/L Thiamet G and protease inhibitors
(SigmaFast)). Aliquots of each crude homogenate were trans-
ferred to two2 ml tubes anddeproteinizedwithperchloric acidor
Ba(OH)2 + ZnSO4. Supernatants were transferred to scintillation
vials and counted to determine 2-[1-14C]-deoxy-D-glucose con-
tent. Tissue-specific glucose uptake rates were calculated as
described previously [16].
2.6. Western Blot Analyses
Approximately 10 mg liver tissue and 25 mg adipose tissue
were homogenized (PRECELLYS® 24, USA) in ice-cold lysis
buffer (pH 7.4, 10% glycerol, 1% IGEPAL, 50 mmol/L Hepes,
150 mmol/L NaCl, 10 mmol/L NaF, 1 mmol/L EDTA, 1 mmol/L
EGTA, 20 mmol/L sodium pyrophosphate, 2 mmol/L sodium
orthovanadate, 1 mmol/L sodium-pyrophosphate, 5 mmol/L
nicotinamide, 4 μmol/L Thiamet G and protease inhibitors
(SigmaFast, Sigma-Aldrich, USA)). Homogenates were incubat-
ed end-over-end for 45 min (4 °C), followed by centrifugation at
16,000g for 10 min (4 °C). Supernatants were stored in aliquots
at −80 °C until further analysis. Protein concentration was
measured by BCA (#23,223 and #23,224, Thermo Scientific, USA)
according to the manufacturer's instructions. Western blot
analyses were performed as previously described [17] using the
following antibodies: anti-ACCβ Ser79 phosphorylation (#07-
303, Upstate Biotechnology, USA), anti-AKT Thr308 phosphory-
lation (#9275, Cell Signaling Technologies, USA), anti-AKT
Thr473 phosphorylation (#9271, Cell Signaling Technologies,
USA), anti-AKT 2 (#3063, Cell Signaling Technologies, USA).
2.7. Isolation of Intestinal Epithelial Cells (IECs)
The small intestine was sectioned in 8 equal segments. The
5th and the 8th segments, starting from duodenum, were
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for isolation of the intestinal epithelial cells. These seg-
ments were flushed with cold PBS buffer, cut open in the
length and fractioned in 0.2–0.5 cm pieces. Samples were
placed on ice and separately incubated in 5 ml of buffer
(Matrisperse cell recovery solution, Corning, USA) for 40 min
allowing epithelium detachment [19,20]. Efficient recovery
of crypt and villi and viability of the epithelial cells were
controlled on a microscope following a trypan blue (Sigma-
Aldrich, USA) staining. Cells were centrifuged at 10,000g for
2 min and snap frozen in liquid nitrogen. Total RNA was
extracted with TRIzol reagent (Invitrogen, USA), and RNA
quality was assessed on a Bioanalyzer (Agilent, USA) by RIN
value (28S/18S ratio). Samples with a RIN value below 7 were
excluded.
2.8. Quantitative PCR
Total RNA of adipose tissues was extracted by TRIreagent®
(Sigma-Aldrich, USA) according to manufacturer's protocol
using PRECELLYS® 24 for homogenization. One microgram of
RNA was transcribed into cDNA by reverse transcriptase
(Invitrogen, USA). Quantitative PCR analyses were performed
using the SYBR Green qPCR Master mix (Thermo Scientific,
USA) and the Stratagene Mx3000P qPCR System. Primer
sequences are summarized in Supplementary Table S1.
2.9. 16S rDNA Amplicon Sequencing and Bioinformatics
Bacterial DNA from cecal and colon samples was extracted
using a NucleoSpin soil kit (Macherey-Nagel, Germany)
according to manufacturer's instructions. DNA yield and
integrity were assessed using a Nanodrop (Thermo Scientif-
ic, USA) and agarose gel electrophoresis, respectively. PCR-
based library formation targeting the 16S rRNA gene's
variable region 4 (V4) was performed as previously described
[21]. The PCR products were purified using Agencourt
AMPure XP (Beckman Coulter, USA) beads and pooled in
equal concentrations. Sequencing was performed using an
Illumina MiSeq with V2 PE500 cartridge (500 cycles). The
generated data was analyzed using QIIME [22] v1.9.1 with
default settings. UCHIME [23] was used for chimera checking
and UCLUST [24] for de novo OTU-picking based on 97%
sequence similarity. Bacterial taxonomy was assigned using
the RDP-classifier [25] and Greengenes [26] database v13.8.
Subsequent analysis was performed in R v3.2.3 using the
Phyloseq [27], metagenomeSeq [28] and Vegan [29]. Low-
abundance operational taxonomic units (OTUs) were filtered
from the data by removal of OTUs present in fewer than 3 of
the samples or with a relative abundance across all samples
of less than 0.005%. The data used for the analysis contained
on average 18.494 ± 3.422 (SD) sequences per sample after
filtering. Analysis of bacterial differential abundance was
performed on data normalized with metagenomeSeq using
cumulative-sum scaling. In addition, the statistical analyses
using metagenomeSeq were performed on data filtered
based on effective sample sizes, where taxa were not
included if they had fewer than X effective number of
positive samples, where X is the median of estimated
effective samples per feature.2.10. Histology Examination and Adipose Tissue Histology
Liver and adipose tissues were fixed in 4% phosphate
buffered paraformaldehyde, dehydrated, and paraffin em-
bedded. Five micrometer sections from 6 to 8 mice of
epididymal white adipose tissue (eWAT) and inguinal
white adipose tissue (iWAT) were stained with hematoxylin
and eosin (H&E). One representative micrograph of each
group is shown, and 2 sections of adipose tissue depots from
each mouse were measured by drawing and used for
quantification of mean cell diameter using Image J open
source software.
2.11. Histopathological and Immunohistochemical Analysis
of Mouse Liver Tissue
Preparation of liver sections and histopathological techniques
were performed according to standard protocols. Two inde-
pendent observers performed all histological assessments in
a blinded fashion. We used the established NAFLD activity
score (NAS) for evaluation of H&E stained random liver
sections as described elsewhere [30]. Briefly, a score of 0 to 2
excludes non-alcoholic steatohepatitis (NASH), a score of 3–4
defines “borderline NASH”, whereas a score of 5 and higher
assures the full picture of NASH.
2.12. Lipid Profile and Thin-Layer Chromatography
Diacylglycerol (DAG) and triacylglycerol (TAG) were measured
on 5 mg liver and ceramide content was measured on 20 mg
liver by thin-layer chromatography (TLC). Lipids were extract-
ed in chloroform–methanol (2:1) [31] and dissolved in chloro-
form as previously described [32]. DAG, TAG, and ceramides
were separated on silica-gel coated plates using two different
separate mobile phases consisting of chloroform–methanol–
acetic acid–water (50:50:5:5) followed by petroleum ether–
diethyl ether–acetic acid (120:25:1.5) for DAG and TAG and
chloroform–methanol–acetic acid (98:2:0.5) for ceramides.
Butylated hydroxytoluene (50 mg/L) was added to both of
the mobile phases. The lipids were developed by a 10% copper
sulfate pentahydrate and 8% phosphoric acid solution at
120 °C for 15 min for DAG and TAG and at 140 °C for 10 min
for ceramides. The silica coated plates were visualized on a
Typhoon FLA 7000 IP fluorescent scanner and analyzed
according to weight using ImageQuant TL (GE Healthcare
Life sciences, United Kingdom).
2.13. Immuno Assays
Plasma insulin, adiponectin, and tumor necrosis factor alpha
(TNF-α) were analyzed on the MSD platform (Mesoscale,
USA), while serum amyloid A (SAA) was analyzed by
standard ELISA (Abcam, USA) according to the manufac-
turers' protocol.
2.14. Statistical Analyses
Data are presented as mean ± SEM. All time-dependent
analyses were evaluated by two-way repeated measures
(RM) ANOVA, Dunnett post hoc test. Time-independent
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hoc test. Bacterial composition was examined using the
metagenomeSeq package and adonis test in R and correla-
tion analyses were examined by Spearman rank correlation
test, adjusted for multiple comparisons by Benjamin and
Hochberg false discovery rate (FDR) test. qPCR data on IECs
were log (Ln) transformed prior statistical analyses due to a
non-Gaussian distribution. Statistical significance was set
at p < 0.05 and the different levels of significance were set at
* = p < 0.05, ** = p < 0.01, *** = p < 0.001.Fig. 1 – High-fat diets induce glucose intolerance independently
fed either a high-fat-high-protein (HFHP), a high-fat-intermediat
8 weeks. A) Bodyweight development. B) Lean bodymass 5 week
D) and E) feed consumption. F) HOMA-IR 6 weeks post diet initia
Glucose tolerance test 6 weeks post diet initiation. I) Plasma insu
fasted mice. Data are presented as mean ± SEM. n = 6 mice per g
experiments. F and I: One representative out of 2 independent ex
post hoc test. In H: # indicates difference between HFHP and LFD
difference between HFNP and LFD.3. Results
3.1. High-Fat Diets Induce Glucose Intolerance Indepen-
dent of Protein and Sucrose Content
We used 3 isoenergetic HFDs designated HFHP, HFIP and HFNP
with matched fat content (45% energy from fat) and a stepwise
increased protein:carbohydrate ratio, and compared the results
to a LFD reference group. To determine the influence of dietaryof background diet and obesity. 8-week-old male mice were
e-protein (HFIP) or a high-fat-normal-protein (HFNP) diet for
s post diet initiation. C) Fat mass 5 weeks post diet initiation.
tion. G) Insulin tolerance test 5 weeks post diet initiation. H)
lin change from prior to 5 min after a glucose bolus in 5-h
roup. A–E, G–H: One representative out of 3 independent
periments. 1- and 2-way ANOVAwhere appropriate, Dunnett
; $ indicates difference between HFIP and LFD, * indicates
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mice empirically are known to be less prone to DIO. According-
ly, body weight and fat composition were similar between
groups (Fig. 1A–C). LFD-fedmicehad ahigher feed intake (grams
of feed consumed) than HFD-fed mice. This was most likely a
consequence of a less energy dense diet (Table 1), as the calorie
intake was similar between the groups (Fig. 1D and E, respective-
ly). These findingswere replicated in 3 independent experiments
(n = 6). In this experimental setting, we were able to obtain
information on the extent to which macronutrient composition
affected whole-body metabolism without confounding effects of
weight gain. Compared to LFD reference mice, 5 weeks of HFD
feeding did not affect the blood glucose response to a
single insulin bolus regardless of the protein:carbohydrate ratio
(Fig. 1G). However, all HFD-fed groups had reduced glucose
tolerance by 6 weeks of HFD feeding (Fig. 1H), suggesting that
HFDs impaired glucose homeostasis independent of weight gain
and protein:carbohydrate ratio. The observed discrepancy
between glucose intolerance (Fig. 1H) and systemic insulin
sensitivity (Fig. 1F–G) could indicate impaired insulin secretion
capacity. However, glucose-stimulated insulin secretion mea-
sured 5 min post glucose bolus was indistinguishable between
groups (Fig. 1I).3.2. Intestinal Alterations in the Microbiome Potentially
Translate to Increased Gluconeogenesis in the Small Intestine
of HFD-Fed Mice
The difference between glucose tolerance and insulin sensi-
tivity prompted us to investigate whether alterations in the
gut might be involved. A possible scenario would involve diet-
dependent alterations in the composition of the gut
microbiota, which subsequently could affect intestinal gene
expression disturbing metabolic homeostasis. Consequently,
we analyzed the intestinal microbiota composition based on
16S rDNA amplicon sequencing. We observed a pronounced
separation between the colonic and cecal microbiota in all
HFD-fed mice and the LFD-fed reference mice (Figs. 2A–C and
S1A–C). Among the HFD-fed mice only the HFHP and HFIP
groups separated significantly (adonis unweighted unifrac
p = 0.023). A higher relative abundance of a single family,
namely S24-7 from the Bacteroidetes phylum was the main
difference comparing the HFHP with the HFIP group (Figs. 2D
and S1D). Despite the observed changes in the S24-7 abun-
dance, our data strongly suggest that in these settings, dietary
fat is a stronger driver of alterations in the composition of the
gut microbiota than the amount and/or ratio between dietary
carbohydrate and protein.
Intestinal epithelial cells (IECs) are ‘first line responders’ to
dietary constituents and key in intestinal gluconeogenesis
[33]. Intestinal gluconeogenesis accounts for up to 20% of host
glucose production [34] and can therefore significantly affect
host glucose homeostasis [35,36]. Moreover, IECs have im-
mune modulatory potential [37] releasing pro-inflammatory
cytokines to the portal circulation, thereby potentially aggra-
vating hepatic insulin resistance. We therefore analyzed gene
expression in ileal and jejunal IECs. Compared to the LFD-fed
reference mice, we observed significant induction of expres-
sion of Nos2, Tnfa, and Il23a in the jejunum of HFHP fed mice,whereas mice fed the HFNP diet exhibited induction of Nos2
and Il1b. In contrast, expression of Il10 and Il13 tended to
decrease in mice fed either of the HFDs. In the ileum, no
significant changes in expression of these cytokines were
observed (Fig. 2E–F). Interestingly, in all HFD-fed mice,
irrespective of the ratio between carbohydrate and protein,
we observed a striking induction of Pck1 and G6pc both in the
jejunum and the ileum (Fig. 2H), suggesting that increased
intestinal gluconeogenesis may contribute to the observed
impaired glucose tolerance.
3.3. Protein:Carbohydrate Ratio Modulates Liver Histology
To further investigate possible mechanisms contributing to the
observed impaired glucose tolerance, we investigated whether
cytokines released from the intestine had affected liver metab-
olism, including accumulation of lipids. None of the HFD-fed
mice exhibited ectopic lipid accumulation as determined by
analysis of hepatic levels of TAG, DAG, and ceramides (Fig. 3A).
Furthermore, serum amyloid A, an acute phase protein with
high dynamic range, primarily reflecting hepatic secretion, and
a potential biomarker of insulin resistance [38], did not differ
between groups (Fig. S2a). However, immunohistochemical
analyses revealed a borderline increase in the NAFLD activity
score in mice fed the HFNP diet (Fig. 3B–C). This finding
suggested that the protein:carbohydrate ratio in connection
withHF-feedingmay affecthepaticmetabolism inamanner not
detectable by biochemical analysis of lipid accumulation, and
that the HFDs with high and intermediate protein:carbohydrate
ratio counteracted this increase in the NAFLD activity score.
3.4. Tissue-Specific Alterations in Insulin-Stimulated
Glucose Uptake in Response to HFD Feeding
To further examine the metabolic alterations associated with
theHFD-feeding,we determinedwhole-body insulin sensitivity
and tissue-specific insulin-stimulated glucose uptake by
performing a hyperinsulinemic euglycemic clamp experiment
in cohorts ofmice challenged by the 4 different diets (Fig. 4A). In
parallel to the decreased glucose tolerance observed during
GTT, the glucose infusion rate under insulin-stimulated condi-
tions (Fig. 4B) was decreased in all HFD-fed mice compared to
LFD-fed reference mice. This observation was marginally
different under steady state conditions (Fig. 4C), where only
HFHP and HFIP reached the level of statistical significance. For
glucose disappearance rate (Fig. 4D), only the HFIP group was
significantly different from the LFD reference mice, albeit all
HFD-fed mice trended towards decreased glucose disappear-
ance. All HFD-fed groups appeared to have sustained EGP under
clamped condition (Fig. 4E), indicating decreased insulin-medi-
ated suppression of gluconeogenesis. The apparently sustained
EGP was, however, not significantly different from the LFD
reference group, presumably due to insufficient power (n = 4–7
mice per group). Still, sustained EGP was unlikely to be the only
mechanism behind the observed glucose intolerance. Accord-
ingly, we examined insulin-stimulated glucose disposal in
peripheral tissues. Irrespective of the diet composition, clamped
mice had comparable insulin-stimulated glucose uptake in
soleus, extensor digitorum longus (EDL), and tibialis anterior
(TA) muscles (Fig. 4F). However, we observed a significant
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Fig. 3 – The dietary protein:carbohydrate ratio affects NAFLD development. Mice were fed experimental diets for 8 weeks
before tissues were either fixed in paraformaldehyde and prepared for paraffin embedding, or snap frozen in liquid nitrogen.
All mice were euthanized in the morning. They had free access to feed. A) Hepatic lipid accumulation. B) NAFLD activity score
evaluated by inspection of images from C. C) H&E stains of lever sections, one representative out of 4–6 images per group. A–B:
Data are represented as mean ± SEM. 1-way ANOVA, Tukey post hoc test. * depicts difference between the labeled group and
the HFIP-fed group. n = 6–8 mice per group.
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HFD-fed mice compared to LFD reference mice, and a tendency
to decreased glucose uptake in eWAT, but no intergroup
variation in brown adipose tissue of clamped mice (Fig. 4G).
3.5. Insulin Signaling is Impaired in iWAT of HFD Fed Mice
The above results prompted us to investigate adipose tissue
morphology and function. All HFD-fed groups displayed
enlarged adipocytes in both eWAT and iWAT (Fig. 5A–B)
despite a lean phenotype and uniform fat mass between
groups. Serum fatty acids and TAG concentrations were not
altered between groups; neither under basal nor clamped
conditions (Fig. S2D–E). In keeping with the marked decreaseFig. 2 – Intestinal alterations in HFD-fed mice affect expression o
Principle Component Analysis (PCoA) plot using unweighted Un
differed significantly from that of the LFD control group (adonis te
depicted allowing better separation of the experimental diets. Th
and HFIP fed mice differed significantly from each other (adonis t
microbial communities at the family level in the colonic samples
two OTUs with the highest relative abundance found to differ si
Inflammatory gene expression profile in IECs of jejunum. F) As i
ileum. G) and H) Gene expression of gluconeogenic genes in jeju
1-way ANOVA, Dunnett post hoc test. * indicates difference betw
different from the HFIP group (n = 5–8 mice per group).in glucose uptake particularly in iWAT, we focused our
subsequent analyses on this depot.
AKT phosphorylation at Thr308 and Ser473 under insulin-
stimulated conditions did not differ between groups when the
statistical analyses were run on data from each phosphoryla-
tion site separately (Fig. 5C). However, performing a two-way
ANOVA on the combined data from both phosphorylation sites
revealed a significant main effect of “diet” (p = 0.028), and
subsequent posthoc tests using the Dunnett's method with the
LFD group as control group showed a significant difference
between LFD and the HFNP groups (p = 0.021), and borderline
significant differences between LFD and HFHP (p = 0.055) and
LFD and HFIP (p = 0.068). Thus, effects of insulin on AKT
signaling are generally reduced in all HFD-fed groups.f genes involved in gluconeogenesis in the small intestine. A)
ifrac distance. The colonic microbiome of all HFD-fed mice
st: p < 0.05). B) As in A, except here only the HFD-fedmice are
e microbiome composition of colonic samples from the HFHP
est: p = 0.023). C) Taxa summary plot of relative abundance of
. D) Relative abundance of the bacterial family S24-7 and the
gnificantly between mice fed the HFHP and HFIP diets. E)
n E except this panel shows the gene expression in IECs of
num and ileum. D–H: Data are presented as mean ± SEM.
een the labeled group and LFD reference group, # indicates
Fig. 4 – Hyperinsulinemic euglycemic clamp reveals tissue-specific alterations in insulin-stimulated glucose uptake in
response to HFD. Mice were fed experimental diets for 7 weeks before insertion of catheters into the jugular vein and carotid
artery, respectively. After surgery, mice were allowed to recover for 6 days before the clamp. A) Blood glucose during the two-
hour clamp. B) Glucose infusion rate needed to stabilize blood glucose level (A) under continuous and fixed insulin infusion. C)
Steady state glucose infusion rate. D) Rate of glucose disappearance before and during clamp. E) Hepatic glucose production
before and during clamp. F) Insulin-stimulated glucose uptake in muscles. G) Insulin-stimulated glucose uptake in adipose
tissue. Data are presented as mean ± SEM. n = 4–7 mice per group. 1- and 2-way ANOVAwhere appropriate, Dunnett post hoc
test. In B: # indicates difference between HFHP and LFD; $ indicates difference between HFIP and LFD, * indicates difference
between HFNP and LFD. In all other panels: * indicates difference between labeled column and LFD. TA: tibialis anterior, EDL:
extensor digitorum longus.
1714 M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 6 5 ( 2 0 1 6 ) 1 7 0 6 – 1 7 1 9Reduced AMP-activated protein kinase (AMPK) activity in
WAT has been linked to insulin resistance in humans [39],
and acetyl-CoA carboxylase (ACC) phosphorylation mirrors
AMPK activity in both muscles and adipose tissue [40,41]. Wefound significantly decreased phosphorylation of ACC at
Ser79 (p = 0.0015 and p = 0.0017, respectively, Fig. 5D) in
HFHP- and HFIP-fed mice, suggesting a decreased activity of
AMPK in iWAT of HFHP- and HFIP-fed mice.
Fig. 5 – Insulin signaling is impaired in iWAT of HFD-fed mice. Mice were fed experimental diets for 8 weeks before tissues
were either fixed in paraformaldehyde and prepared for paraffin embedding or snap frozen in liquid nitrogen. All mice were
euthanized in the morning. They had free access to feed. A) Histology section of paraffin embeddedWAT. B) Adipocyte size as
visualized in A. C) and D) phosphorylation of AKT and ACC, respectively. E) Serum adiponectin. In B–E: Data are presented as
mean ± SEM. n = 5–8 mice per group. 1-way ANOVA, Dunnett post hoc test. * indicates difference between labeled column and
LFD. In C: As a measure of a general effect of AKT phosphorylation a 2-way ANOVA, Dunnett post hoc test was performed. The
HFDs were compared to the LFD reference group an adjusted for multiple comparisons showing a main effect on AKT
phosphorylation in HFNP-fed mice (HFHP: p = 0.0547; HFIP: p = 0.0848; HFNP: p = 0.0205).
1715M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 6 5 ( 2 0 1 6 ) 1 7 0 6 – 1 7 1 9Adiponectin is an insulin-enhancing adipokine [42]
exerting both autocrine and paracrine functions. At the
autocrine level, adiponectin stimulates lipid storage and
enhances both insulin-stimulated glucose uptake [43] and
AMPK activation [44]. HFHP- and HFIP-fed mice had reduced
levels of circulating adiponectin compared to LFD reference
mice, while HFNP-fedmice only trended towards a reduction in
serumadiponectin (Fig. 5E). Interestingly, the pro-inflammatory
cytokine, TNF-α, has been shown to induce a lowering of
adiponectin release in adipose tissue of lean, but not obese
individuals [45]. As neither circulating TNF-α protein nor WATmRNA levels of Tnfa (Fig. S2B and C–D, respectively) were
different between LFD and HFD-fed groups, TNF-α may not
explain the observed reduced adiponectin levels. Inspection of
H&E stained tissue sections revealed no increase inmacrophage
infiltration and crown like structures (CLSs) into white adipose
tissue (data not shown), and we did not observe alterations in
mRNA expression of macrophage chemo-attractant protein-1
(Mcp-1), or the inflammatory regulators, interleukin (Il)1b and Il6
(Fig. S2C–D). Finally, we asked if the serum protein levels of
another macrophage chemo-attractant, C-X-C motif chemokine
10 (CXCL10), an anti-inflammatory molecule, IL10, as well as
Table 2 – Spearman correlation analysis.
Variable 1 Variable 2 r p
Fat Weight change 0.39 0.035
Fat Adipocyte size, eWAT 0.32 0.009
Fat G6pc, jejunum 0.32 0.008
Fat Serum adiponectin −0.47 0.033
Protein Serum adiponectin −0.54 0.012
Carbohydrate (sucrose) Il13, jejunum −0.51 0.025
Weight change Pck1, jejunum 0.47 0.041
Adipocyte size, eWAT Il10, jejunum −0.54 0.021
Adipocyte size, iWAT Adipocyte size, eWAT 0.71 0.00032
Adipocyte size, iWAT Nos2, jejunum 0.52 0.033
Adipocyte size, iWAT Pck1, jejunum 0.56 0.018
Adipocyte size, iWAT G6pc, jejunum 0.58 0.015
iNOS, jejunum Il1β, jejunum 0.69 0.001
iNOS, jejunum Il22r, jejunum 0.57 0.011
iNOS, jejunum Pck1, jejunum 0.61 0.005
iNOS, jejunum G6pc, jejunum 0.53 0.19
IL-1β, jejunum Il22r, jejunum 0.64 0.003
IL-1β, jejunum Pck1, jejunum 0.48 0.038
IL-1β, jejunum G6pc, jejunum 0.46 0.045
IL-22r, jejunum Pck1, jejunum 0.46 0.049
IL-22r, jejunum G6pc, jejunum 0.56 0.013
IL-22r, jejunum Serum adiponectin −0.53 0.019
Serum adiponectin Il10, jejunum 0.48 0.038
Serum adiponectin Il22r, jejunum −0.53 0.019
The following variables were compared: 1) inflammatory gene
expression in jejunum. 2) Gluconeogenic gene expression in
jejunum. 3) Serum adiponectin. 4) Weight change. 5) Adipozyte
size of iWAT and eWAT. 6) Sucrose, fat, and protein intake. Only
correlations that met the criteria of p <0.05 and r ≥0.3 with a
subsequent FDR <0.05 are depicted. n = 17–19 per correlation.
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mice. Both resistin and CXCL10 have been reported to be
increased in human type 2 diabetic patients [46,47], whereas
serum IL10 levels appear to be decreased in type 2 diabetic
patients [48]. However, none of these markers differed between
the four groups of mice (Fig. S2B).
3.6. Dietary Fat is a Predominant Driver of Diet-Induced
Immuno-Metabolic Alterations
Investigating the correlation between jejunal gene expres-
sion, adipocyte size, adiponectin secretion and weight change
by Spearman correlation analysis indicated a correlation
between intestinal inflammatory profile and expression of
gluconeogenic genes (Table 2). Bridging intestinal immunity
to whole-body metabolism, the inducible isoform of nitric
oxide synthases, NOS2, involved in pro-inflammatory im-
mune responses, was found to positively correlate with
adipocyte size in iWAT (Table 2, r = 0.52, p = 0.033), whereas
the anti-inflammatory cytokine IL10 correlated negatively
with adipocyte size in eWAT (Table 2, r = −0.54, p = 0.021).
Spearman correlation analyses including dietary constituents
revealed fat as the most prominent driver, correlating
positively with weight change (Table 2, r = 0.39, p = 0.035),
adipocyte size in eWAT (Table 2, r = 0.32, p = 0.009), and also
with jejunal G6pc expression (Table 2, r = 0.32, p = 0.008),while correlating negatively with serum adiponectin (Table 2,
r = −0.47, p = 0.033). Sucrose was inversely correlated with
jejunal transcripts of Il13 (Table 2, r = −0.51, p = 0.021), and
protein intake was, like fat intake, inversely correlated with
serum adiponectin (Table 2, r = −0.54, p = 0.012). Interestingly,
serum adiponectin levels were not correlated with expression
of markers for intestinal gluconeogenesis (Pck1: r = −0.27, p =
0.257; G6pc: r = −0.33, p = 0.166) or adipocyte size, albeit a
borderline correlation between serum adiponectin and eWAT
cell size (p = 0.053, n = 18) but not iWAT cell size (p = 0.204, n =
17) was observed. In contrast, adipocyte size correlated with
both inflammatory and gluconeogenic jejunum gene
expression (Table 2).4. Discussion
In the present study we demonstrate that HFD consumption
impaired whole-body glucose homeostasis independent of
weight gain and irrespective of the protein:carbohydrate ratio.
The observed glucose intolerance of HFD-fed animals may be
a consequence of elevated gluconeogenic potential in intes-
tinal epithelial cell which is supported by our finding of
increased expression of gluconeogenic genes in the epithelial
cells of the jejunum and ileum, and the sustained EGP during
the hyperinsulinemic euglycemic clamp experiments in these
animals. We did not observe any impairment of glucose-
stimulated insulin secretion as measured 5 min after admin-
istration of a glucose bolus, and inflammation markers in
adipose tissues were not elevated. However, insulin-stimu-
lated glucose uptake in iWAT was impaired and was
accompanied by decreased insulin-dependent phosphoryla-
tion of AKT. Collectively, our data support that diminished
insulin-dependent glucose uptake in adipose tissues and
increased intestinal gluconeogenesis contribute to the ob-
served impaired glucose tolerance.
Diets high in protein have been suggested to promote
leanness through increased satiety mediated by an augment-
ed intestinal gluconeogenesis [36]. Yet, we did not find
changes in gene expression of gluconeogenic genes, or
changes in feed intake as a function of dietary protein
content. Rather, we observed that induction of key genes
involved in intestinal gluconeogenesis correlated with high
fat intake. Dietary fat intake has previously been found to be a
more powerful driver of changes in the composition of the gut
microbiota than the protein:carbohydrate ratio [49]. Our
analyses confirm this finding and further show that fat intake
correlated with more changes than protein and sucrose
intake combined, pointing to fat intake independent of weight
gain as a key determinant for metabolic regulation.
Because dietary long chain fatty acids, protein and simple
carbohydrates are digested in the small intestine, particularly
in jejunum,we hypothesized that diet-induced jejunal immune
alterations might orchestrate subsequent host responses of
glucoregulatory origin. In support of this hypothesis, HFD-
induced intestinal Tnfa expression precedes both obesity and
insulin resistance [50], while gut anti-inflammatory agents
protect against insulin resistance, but not obesity [13]. More-
over, our multivariate analysis revealed that the expression of
1717M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 6 5 ( 2 0 1 6 ) 1 7 0 6 – 1 7 1 9several jejunal inflammatory gene transcripts correlated with
expression of jejunal gluconeogenic gene transcripts.
Despite a similar reduction in glucose tolerance across all
three HFDs examined, our data suggest that background diet,
in this case protein:carbohydrate ratio, may have affected the
‘route of action’. Both serum adiponectin and ACC phosphor-
ylation in iWAT were diminished in HFHP and HFIP-fed mice
compared to LFD reference mice, while HFNP-fed mice were
less affected. In contrast, HFNP-fed mice had decreased
adipose insulin signaling, as determined by AKT phosphory-
lation, compared to the LFD reference group, and increased
NAFLD activity score compared to the HFIP and HFHP fed
mice. HFIP-fed mice had a reduced abundance of OTUs
belonging to the bacterial family S24-7 compared to any of
the tested diets. Furthermore, Spearman correlation analyses
showed that both dietary protein and fat but not sucrose
negatively correlated with serum adiponectin levels. This is of
particular interest since low carbohydrate intake
counterbalanced by a high intake of protein and fat is a
popular tool in weight losing regimes.
One limitationof the current study is the relative lown size in
several of the experiments. Obviously, this affected the statisti-
cal power in the subsequent analysis of the data, and thereby
may have promoted type 2 errors and the risk of accepting
differences as non-significant. Nonetheless, the unique experi-
mental settings applied in this study have enabled us to
decipher how diets high in fat affect whole-body glucose
homeostasis in mice independent of a confounding weight
gain. The detailed physiological assessment of whole-body
insulin sensitivity and tissue-specific glucose uptake, as well as
comprehensive biochemical and histological analyses of a wide
range of tissues and cell types, have provided us with valuable
data that support a role of dietary fat per se to increase the
gluconeogenic potential of intestinal epithelial cells, to contrib-
ute to development of glucose intolerance, and to decrease
insulin-stimulated glucose uptake in adipose tissue. To our
knowledge, no human studies have been conducted in which
these effects of dietary fat have been investigated in the absence
of a confounding weight gain. Results from such studies would
be very interesting and obviously important for proper dietary
guidance of people in need of maintaining or losing weight.Author Contributions
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